Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Department of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Nat Rev Cardiol. 2022 May;19(5):332-341. doi: 10.1038/s41569-021-00631-3. Epub 2021 Oct 22.
Throughout 2021, the medical and scientific communities have focused on managing the acute morbidity and mortality caused by the coronavirus disease 2019 (COVID-19) pandemic. With the approval of multiple vaccines, there is a light at the end of this dark tunnel and an opportunity to focus on the future, including managing the long-term sequelae in patients who have survived acute COVID-19. In this Perspectives article, we highlight what is known about the cardiovascular sequelae in survivors of COVID-19 and discuss important questions that need to be addressed in prospective studies to understand and mitigate these lasting cardiovascular consequences, including in post-acute COVID-19 syndrome. To provide the greatest benefit to these survivors, prospective studies should begin now, with resources made available to monitor and study this population in the coming years.
2021 年期间,医学和科学界一直专注于管理由 2019 冠状病毒病(COVID-19)大流行引起的急性发病和死亡。随着多种疫苗的批准,隧道尽头出现了一线曙光,我们有机会着眼于未来,包括管理急性 COVID-19 后幸存患者的长期后遗症。在这篇观点文章中,我们重点介绍了 COVID-19 幸存者的心血管后遗症方面的已知情况,并讨论了需要在前瞻性研究中解决的重要问题,以了解和减轻这些持续存在的心血管后果,包括在 COVID-19 后综合征中。为了使这些幸存者受益最大,现在就应该开始前瞻性研究,提供资源来监测和研究未来几年的这一人群。